Trial reportOphthalmology2021
Systemic Conditions Associated with Severity of Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management Study.
Trial report in Ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Ocular Surface Disorders in ICU Patients: Evidence-Based Nursing Prevention Strategies.Translational vision science & technology · 2025Pooled it
- Decoding and reconstructing disease relations between dry eye and depression: a multimodal investigation comprising meta-analysis, genetic pathways and Mendelian randomization.Journal of advanced research · 2025Pooled it
- TFOS lifestyle: Impact of societal challenges on the ocular surface.The ocular surface · 2023Pooled it
- Okra eyelid patch versus sodium hyaluronate combined with ofloxacin eye drop in the treatment of meibomian gland dysfunction: a randomized controlled trial.BMC ophthalmology · 2026Trial
- Association between lid margin collarettes and dry eye disease severity in the Dry Eye Assessment and Management (DREAM) study.Eye (London, England) · 2026Trial
- Trial
- Evaluation of the therapeutic effect of estrogen replacement therapy combined with autologous serum therapy in controlling severe dry eye disease in perimenopausal women.Scientific reports · 2025Trial
- Longitudinal Analysis of Tear Cytokine Ratios in Association with Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study.Current eye research · 2025Trial
- Sex-related differences and hormonal effects in the Dry Eye Assessment and Management (DREAM) study.The British journal of ophthalmology · 2023Trial
- Dry Eye Subtypes in the Dry Eye Assessment and Management (DREAM) Study: A Latent Profile Analysis.Translational vision science & technology · 2022Trial
- Self-Propelled HPB@Lip@AB Nanomotors Ameliorate Dry Eye Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ocular IL-1α/IFN-γ Delay the Corneal Wound Healing in Rheumatoid Arthritis Through Mitochondrial Dysfunction and NLRP3 Inflammasome Activation.Investigative ophthalmology & visual science · 2026Article
- Exosome-based therapies for corneal disorders: current status and future perspectives.MedScience · 2026Review
- Approach to the patient: therapeutic mitigation of lacrimal manifestations in thyroid eye disease.The Journal of clinical endocrinology and metabolism · 2026Review
- Current and Developing Therapeutics for Dry Eye Disease: Targeting Ion Channels.Current issues in molecular biology · 2026Review
- Ocular Surface Microbiota-Derived Lipoteichoic Acid Promotes Dry Eye Disease by Inducing Corneal Inflammation.Investigative ophthalmology & visual science · 2026Article
- Elemental Composition Analysis of Sheep Tears Using Particle-Induced X-Ray Emission.Veterinary ophthalmology · 2026Article
- Research progress in animal models of dry eye disease: Types, mechanisms, and application prospects.Animal models and experimental medicine · 2026Review
- Management of Dry Eye Disease Pre- and Post-Cataract Surgery: A Personalized Approach.Journal of personalized medicine · 2026Review
- Ly93 Inhibits Sphingomyelin Synthesis and Attenuates Inflammation and Injury in Dry Eye Conjunctival Organoids.Investigative ophthalmology & visual science · 2026Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeCertain systemic conditions are reported to be risk factors for dry eye disease (DED), but their associations with DED severity are not well studied. We evaluated whether systemic conditions reported to be DED risk factors are associated with severity of DED signs and symptoms.
designSecondary analysis of data from the Dry Eye Assessment and Management Study, a large-scale multicenter randomized clinical trial of patients with moderate to severe DED.
participantsFive hundred thirty-five adult patients with moderate to severe DED from 27 United States centers.
methodsPatients reported their medical history at baseline. They underwent ocular surface examinations and symptom evaluation using standardized protocols at baseline, 6 months, and 12 months. We analyzed the associations of systemic conditions (a systemic disease or smoking history) reported as potential DED risk factors with the severity of DED signs and symptoms using generalized linear regression models adjusted by age, gender, race, and visit.
main outcome measuresDry eye disease symptoms assessed using the Ocular Surface Disease Index (OSDI), 6 DED signs (tear film break-up time, anesthetized Schirmer testing, corneal fluorescein staining, conjunctival lissamine green staining, tear osmolarity, and meibomian gland dysfunction), and a composite signs severity score from 0 to 1 (1 = most severe).
resultsThe mean age was 58 years; 81% were women. More severe DED signs were associated significantly with Sjögren syndrome (mean composite signs severity score 0.52 with disease vs. 0.43 without disease; P < 0.001), facial rosacea (0.47 vs. 0.43; P = 0.002), rheumatoid arthritis (0.47 vs. 0.42; P = 0.002), peripheral artery disease (0.50 vs. 0.43; P < 0.001), and daily smoking history (0.45 vs. 0.43; P = 0.047). Thyroid dysfunction, osteoarthritis, diabetes, irritable bowel syndrome, hypercholesterolemia, hypertension, and hypertriglyceridemia were not associated significantly with DED signs. No conditions were associated significantly with OSDI.
conclusionsIn this large, well-characterized cohort of patients with DED assessed under standardized procedures, patients with certain systemic diseases and smoking history showed more severe DED signs compared with patients without the conditions. The profile of significant DED signs varied by systemic condition, reflecting different DED causes. Understanding the systemic conditions and underlying causes that predispose some patients to severe DED can improve management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.